SPIRITUS: (02-17) A Monthly update from the Respiratory Technology team at the WIMR.


This is the February 2017 newsletter from the RespiTech Group at the Woolcock Institute of Medical Research.

February has seen the commencement of a number of initiatives. Of note, the construction work for the Centre for Lung Cancer Research got underway at the Woolcock. This initiative, for which Paul has been a one of the key leaders, will result in a state-of-the-art research centre for people working in the area of lung cancer research and provide support for a the wider Lung Cancer Research Network.

Also this month, members of the RespiTech group successfully launch a new degree through the School of Medicine. The new Master of Medicine (PharmDev) degree is targeted at individuals working in the medical device and pharmaceutical sectors and offers professional education with respect to the development, registration and production of medicines in Australia and overseas. The Course coordinators for the new degree are Hui Xin Ong (YY), Paul Young and Daniela Traini. You can learn more about the degree here. Also this month, the same team members, traveled up to Brisbane to meet with Prof Scott Bell (QIMR) and a number of other collaborators to establish a new clinical trial in Cystic Fibrosis. The trial will aim to reduce burden of disease through similar and more efficient respiratory therapy.